Artificial Intelligence algorithm can learn the laws of quantum mechanics and speed up drug delivery

Artificial Intelligence can be used to predict molecular wave functions and the electronic properties of molecules. This innovative AI method developed by a team of researchers at the University of Warwick, the Technical University of Berlin and the University of Luxembourg, could be used to speed-up the design of drug molecules or new materials.

Artificial Intelligence and machine learning algorithms are routinely used to predict our purchasing behaviour and to recognise our faces or handwriting. In scientific research, Artificial Intelligence is establishing itself as a crucial tool for scientific discovery.

In Chemistry AI has become instrumental in predicting the outcomes of experiments or simulations of quantum systems. To achieve this, AI needs to be able to systematically incorporate the fundamental laws of physics.

An interdisciplinary team of chemists, physicists, and computer scientists led by the University of Warwick, and including the Technical University of Berlin, and the University of Luxembourg have developed a deep machine learning algorithm that can predict the quantum states of molecules, so-called wave functions, which determine all properties of molecules.

The AI achieves this by learning to solve fundamental equations of quantum mechanics as shown in their paper published in Nature Communications.

Solving these equations in the conventional way requires massive high-performance computing resources (months of computing time) which is typically the bottleneck to the computational design of new purpose-built molecules for medical and industrial applications. The newly developed AI algorithm can supply accurate predictions within seconds on a laptop or mobile phone.

Dr. Reinhard Maurer from the Department of Chemistry at the University of Warwick comments: "This has been a joint three year effort, which required computer science know-how to develop an artificial intelligence algorithm flexible enough to capture the shape and behaviour of wave functions, but also chemistry and physics know-how to process and represent quantum chemical data in a form that is manageable for the algorithm."

The team have been brought together during an interdisciplinary 3-month fellowship program at IPAM (UCLA) on the subject of machine learning in quantum physics.

Prof Dr Klaus Robert-Muller from the Institute of Software Engineering and Theoretical Computer Science at the Technical University of Berlin adds: "This interdisciplinary work is an important progress as it shows that, AI methods can efficiently perform the most difficult aspects of quantum molecular simulations. Within the next few years, AI methods will establish themselves as essential part of the discovery process in computational chemistry and molecular physics."

Professor Dr Alexandre Tkatchenko from the Department of Physics and Materials Research at the University of Luxembourg concludes: "This work enables a new level of compound design where both electronic and structural properties of a molecule can be tuned simultaneously to achieve desired application criteria."

Schütt KT, Gastegger M, Tkatchenko A, Müller KR, Maurer RJ.
Unifying machine learning and quantum chemistry with a deep neural network for molecular wavefunctions.
Nat Commun. 2019 Nov 15;10(1):5024. doi: 10.1038/s41467-019-12875-2.

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...